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Abstract
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Homocysteine thiolactone-induced protein modification (HTPM) is a unique post-translational
protein modification that is recognized as an emergent biomarker for cardiovascular disease.
HTPM involves the site-specific acylation of proteins at lysine residues by homocysteine
thiolactone (HTL) to produce protein homocystamide, which has been found at elevated levels in
patients with coronary heart disease. Herein, we report the development of a novel gold
nanoparticle (GNP) biochemical sensor for detection of protein homocystamide in an in vitro
serum protein-based model system. Human serum albumin (HSA) and human sera were subjected
to HTPM in vitro to produce HSA-homocystamide or serum protein homocystamide, respectively,
which was subsequently treated with citrate-capped GNPs. This GNP sensor typically provided
instantaneous visual confirmation of HTPM in the protein model systems. Transmission electron
microscopy images of the GNPs in the presence of HSA-homocystamide suggest that
modification-directed nanoparticle assembly is the mechanism by which the biochemical sensor
produces a colorimetric signal. The resultant nanoparticle-protein assembly exhibited excellent
thermal and dilutional stability, which is expected for a system stabilized by chemisorption and
intermolecular disulfide bonding. The sensor typically provided a linear response for modified
human sera concentrations greater than ~5 mg/mL. The calculated limit of detection and
calibration sensitivity for the method in human sera were 5.2 mg/mL and 13.6 AU · (μg/mL)−1,
respectively.
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Introduction
An elevated plasma level of the potentially toxic amino acid homocysteine (Hcy) is a known
risk factor for cardiovascular1,2 and neurodegenerative3 diseases such as coronary heart
disease and Alzheimer’s disease, respectively. Although the function of Hcy in the
pathogenesis of these diseases is not yet fully understood, there is considerable evidence that
suggests that Hcy thiolactone (HTL) may contribute to cardiovascular disease.4–7 HTL is a
highly reactive thioester analogue of Hcy synthesized in vivo via enzymatic aminoacyltRNA synthase pathways at a rate proportional to extracellular Hcy concentration.8 Hence,
it is likely that HTL production is elevated in individuals with elevated plasma levels of
Hcy.9 Increased in vivo production of HTL is believed to initiate various detrimental
physiological effects, including vascular tissue damage and formation of early
*
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atherosclerotic lesions.4,10 It has been shown that HTL readily and selectively reacts with
proteins at the ε-amino groups of lysine residues under physiological conditions to yield
highly labile protein homocystamide species.11,12 It is known that HTL-induced protein
modification (HTPM) can be detrimental to protein function because it may lead to
spontaneous intermolecular disulfide bonding to yield protein oligomers.11,13 HTPM may
also result in decreased biological activity, decreased solubility, and increased
immunogenicity for affected proteins.11,14 Moreover, a recent clinical study by Yang et al.
6 reported the discovery of elevated levels of protein homocystamide in individuals with
coronary heart disease. They found a positive correlation between plasma protein
homocystamide levels and the number of major diseased coronary vessels in 254 subjects,
which further supports the validity of protein homocystamide as a biomarker for
cardiovascular disease.
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Considering the status of HTPM as an emerging biomarker for cardiovascular disease, the
development of novel detection methods for protein homocystamide and related
cardiovascular disease biomarkers is of great importance. Our laboratory has developed
several novel organic dye-based colorimetric and fluorimetric sensors for the detection of
various amino thiol disease biomarkers, including cysteine and homocysteine.15–18 Several
of these novel sensors show promise for amino thiol detection in human blood plasma. We
also reported the use of redox indicators for electrochemical detection of glutathione,
another important amino thiol biomarker.19 Our recent work explores new detection
schemes and strategies for investigating the physiochemical properties of protein
homocystamide. For example, we reported the development a rapid capillary electrophoresis
(CE) method for separating mixtures containing oligomeric protein homocystamide derived
from in vitro modified cytochrome c. This CE method was successfully applied to
monitoring the inhibition of HTL-induced protein oligomerization via in situ pyridoxal
tetrahydrothazine formation.20
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Separation techniques such as TLC21 and HPLC22 have also been employed to quantify
protein homocystamide, but few specific detection schemes have been reported. Enzymelinked immunosorbent assays (ELISAs) are perhaps the most commonly used affinity
technique for protein homocystamide determination.6,23 ELISAs are a highly sensitive and
versatile format that can be configured to generate either a colorimetric or a fluorimetric
response, provided that appropriate antibodies are available. Another advantage of ELISA is
the wide commercial availability of 96-well plate kits, which provide a user-friendly
interface that is amenable to high-throughput applications. However, one potential
disadvantage of the use of ELISAs for the detection of HTPM is the time and expense
required to produce and purify sufficient quantities of antibodies specific for protein
homocystamide.24
Metallic nanoparticles may offer an alternative to conventional immunoaffinity methods for
some biochemical sensing applications. One reason is because citrate-capped colloidal gold
nanoparticles can be quickly synthesized using a facile one-step redox reaction and at a
small fraction of the cost of a comparable quantity of monoclonal antibodies.25 In addition,
gold nanoparticles (GNPs) are well suited for use in colorimetric detection applications
because they exhibit intense surface plasmon bands in the visible region of the
electromagnetic spectrum. For instance, dispersed colloidal gold particles having dimensions
on the order of ~10 nm typically have an intense surface plasmon band at approximately 520
nm, resulting in a red-colored solution. Upon aggregation of the GNPs, red-shifted extended
plasmon bands typically appear at ~620 nm, causing a characteristic transition in solution
color from red to purple-violet.26
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The concept of gold probe biochemical sensors originated more than 40 years ago when
Bloomfield devised a colloidal gold test for plasma protein.27 Since then, a multitude of
gold colloid-based biochemical sensors have been reported. This topic has been
comprehensively reviewed in the literature.28–31 GNPs are capable of sensing a wide range
of physiologically relevant small molecules including carbohydrates,32 amino thiol
biomarkers,33,34 and DNA.35,36 GNP-based sensors have also proven useful for a variety
of protein applications such as assessing protein structure37–41 and the detection of various
protein-based analytes, including platelet-derived growth factors,42 steptavidin,43 and
cholera toxin.44
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In general, the utility of GNPs as biochemical colorimetric sensors is based on exploiting the
appropriate biochemical mechanisms in order to stimulate nanoparticle assembly.
Accordingly, it is often necessary to functionalize the nanoparticles with affinity ligands in
order to achieve analyte-specific nanoparticle self-assembly.35,44,45 However, applications
involving the detection of thiol-containing species do not necessarily require the use of
functionalized nanoparticles since gold is intrinsically thiol reactive. For example,
unfunctionalized citrate-capped GNPs have been successfully employed as colorimetric
sensors for various amino thiols including Hcy,33 cysteine,34 and glutathione.34 Amino
thiols tend to readily adsorb onto the surface of colloidal gold particles via chemisorptiontype interactions. Nanoparticle assembly has been shown to occur via noncovalent
electrostatic-type interactions between the amino and carboxylic acid groups.33,34
Herein, we report the use of citrate-capped colloidal GNPs as a sensor for HTPM. Scheme 1
illustrates the proposed mechanism for the colorimetric GNP sensor. In the presence of
unmodified protein, the nanoparticles interact in a nonspecific manner with individual
protein molecules but remain randomly dispersed throughout the protein solution. As a
result, the sensor solution retains the characteristic red color of dispersed colloidal GNPs. In
contrast, the nanoparticles bind with the HTL-modified proteins via chemisorption-type
binding (Au-S-R), which can facilitate nanoparticle assembly via cross-linking. The
nanoparticle assembly is further stabilized by intermolecular disulfide bonding (R-S-S-R)
between protein homocystamide species. The scale bars are shown to emphasize the relative
difference in interparticle distances for dispersed and assembled GNPs, respectively. UV-vis
absorption spectroscopy and transmission electron microscopy (TEM) were employed to
investigate the assembly behavior of colloidal gold nanoparticles in response to protein
homocystamide. To the best of our knowledge, direct colorimetric detection of serum
protein homocystamide using GNPs has not been previously reported.

Materials and Methods
NIH-PA Author Manuscript

Reagents
L-Homocysteine thiolactone hydrogen chloride, hydrogen tetrachloroaurate trihydrate,
trisodium citrate, EDTA, and all other reagents used for the preparation of buffer and serum
protein solutions were obtained from Sigma-Aldrich (St. Louis, MO) at the highest purity
available and used as received. Ultrapure water (18.2 MΩ) was obtained from an Elga model
PURELAB Ultra water filtration system.
Synthesis and Characterization of Gold Nanoparticles
Citrate-capped GNPs, ca. 13 nm diameter, were synthesized using the well-known
Turkevich–Frens method.25,46 Briefly, a solution of hydrogen tetrachloroaurate trihydrate
was prepared in water and heated to reflux while stirring, followed immediately by addition
of a 40 molar excess of freshly prepared trisodium citrate–water solution, which initiated the
reduction of the hydrogen tetrachloroaurate trihydrate. The aurate–citrate solution was
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allowed to reflux for approximately 25 min or until completion of the redox reaction as
indicated by a change in solution color from faint yellow to dark red. The excess citrate in
solution creates a negatively charged surface on the GNPs, thereby minimizing nonspecific
GNP aggregation postsythesis.25 The resultant GNP solution was allowed to cool to room
temperature prior to storage in an amber glass bottle. Aurate (1.0 mM) was reduced in 40
mM citrate, resulting in a GNP stock solution of 1.0 mM, assuming complete reduction of
the gold. GNP solutions were purified using a 0.1 μm polyetrafluoroethylene syringe filter
devices. Nanoparticle size was confirmed using dynamic light scattering (DLS) and
transmission electron microscopy (TEM).
Preparation of Homocysteine Thiolactone-Modified Protein
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The protein homocystamide stock solutions used in this study were synthesized using
procedures similar to those previously reported by Jakubowski.11 Briefly, essentially fatty
acid free human serum albumin purchased from Sigma-Aldrich (St. Louis, MO) was
dissolved in pH 7.4, 100 mM, sodium phosphate buffer containing 0.2 mM EDTA and
incubated at 25 °C in the presence of 4.6 mM HTL for 4 h at room temperature. The posttranslational modification reaction was quenched by filtering the protein reaction solution
through a 10 kDa molecular weight cutoff centrifugal membrane device (Millipore,
Billerica, MA) to remove any unreacted HTL as well as other low molecular weight
byproducts such as Hcy. The protein retentate was rinsed twice with 1 mL buffer aliquots to
remove nonspecifically bound HTL or Hcy. The rinsed modified protein was promptly
reconstituted with buffer to obtain the protein homocystamide stock solution.
Electrospray ionization mass (ESI-MS) was used to verify the post-translational
modification of HSA by HTL. The mass spectrometry data indicates that the in vitro
modification reaction protocol used in this study is efficient and typically yields an
extensively modified HSA solution. The majority of the resultant HSA species typically
contained ~1–4 Hcy per protein molecule postmodification. A substantial signal
corresponding to dimeric HSA was also detected due to modification-induced
oligomerization. On the basis of these findings, the concentrations of the HSA and serum
homocystamide solutions are reported in units of mg/mL or μg/mL, assuming complete
modification. Mass spectra (Figure S1) and additional discussion are provided in the
Supporting Information.
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Unless otherwise noted, protein homocystamide standard solutions were prepared by
diluting the stock solution with phosphate buffer. Excess biological materials were heat
sterilized prior to disposal in an approved biohazard waste container. All appropriate safety
apparels such as protective gloves, clothing, and eyewear were worn while handling the
potentially biohazardous human serum protein material.
Colorimetric Detection of HTL-Modified Protein Using a Gold Nanoparticle Sensor
Protein homocystamide solutions were immediately treated with the GNP sensor in order to
minimize the loss of colorimetric response due to spontaneous intermolecular disulfide
bonding between modified proteins and other miscellaneous auto-oxidation processes. The
protein homocystamide solutions used in this study were not treated with a disulfide
reductant. Unless otherwise indicated, a 100 μL aliquot of the protein homocystamide or
control solution was treated with 200 μL of 1.0 mM GNP stock solution at room
temperature. Changes in the visible absorption due to the GNPs and the nanoparticlemodified protein complex were monitored immediately at 520 and 620 nm, respectively.
The UV absorption associated with the protein was monitored between 220 and 280 nm.
Protein–sensor solutions were typically diluted 2-fold prior to measuring UV–vis absorption.
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Absorption measurements were acquired using a Shimadzu, model UV-3101PC UV-visNIR spectrophotometer with either quartz (UV–vis) or disposable polystyrene (visible only)
reduced volume cells. DLS measurements were performed using a Malvern Zetasizer Nano
ZS (Worcestershire, U.K.). TEM images were acquired with a JEOL model 100CX
transmission electron microscope using an acceleration voltage of 80 kV. TEM specimens
were prepared by adsorbing a thin layer of the sensor–protein solution onto carbon-coated
grids followed by air drying. The sample grids were treated with 2% uranyl acetate staining
reagent prior to TEM imaging.

Results and Discussion
Evaluation of GNPs as a Serum Protein Sensor
A preliminary assessment of the proposed GNP sensor was performed using the model
protein human serum albumin (HSA). HSA was chosen for these studies because it is a
major protein constituent in human serum, accounting for approximately one-half of the
total serum protein. In addition, it is known that highly stable albumin–GNP conjugates are
readily obtained via adsorption interactions under physiological pH and ionic strength
conditions.40,47,48 However, it was necessary to evaluate the behavior of the proposed
HSA-GNP system under the conditions used for these studies.
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Figure 1 is an image of cuvettes containing equivalent concentrations of the GNP sensor
(~0.3 mM) in the presence of either HSA or HSA-homocystamide (0–85.2 mg/mL)
dissolved in phosphate buffer (100 mM at pH 7.4). The protein concentration range used for
this study encompasses the expected physiological concentration range for HSA in human
plasma, ~34–54 mg/mL.49 As expected, the GNPs were only sparingly soluble in the
phosphate buffer in the absence of HSA. The resultant metallic gray-colored suspension
shown in Figure 1a is slightly opaque due to scattering from salt-induced aggregation and
precipitation of the GNPs. This behavior is attributed to the citrate-capped GNPs becoming
destabilized by the relatively high ionic strength of the phosphate buffer.50
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Cuvettes containing unmodified HSA (9.2–85.2 mg/mL) are shown in Figure 1b. The
nanoparticles remain stable and dispersed in the presence of unmodified HSA, as indicated
by the reddish-pink color of the sensor solutions. Notably, there is no discernible change in
the color of the sensor solutions in response to increasing concentrations of unmodified
HSA, which suggests that non-specific nanoparticle assembly does not occur in the presence
of unmodified HSA. Furthermore, the UV–vis absorption spectra shown in Figure 2a are
similar to those previously reported for bovine serum albumin–GNP conjugates dissolved in
10 mM phosphate at pH 7.0.40
The GNP sensor produced a significant colorimetric signal in response to increasing
concentrations of protein homocystamide, which is clearly visible in Figure 1c. The sensor
solutions transition from a reddish-pink to a deep purple-violet color, which is easily
distinguishable from the highly scattering metallic gray-colored suspension produced in the
absence of protein due to salt-induced nanoparticle aggregation.
The corresponding UV–vis absorption spectra for sensor–protein solutions collected
approximately 20 min after treatment with the GNPs (Figure 1b, c) are provided in Figure 2.
The absorption spectra shown in Figure 2a indicate the absorption maximum (λmax) for the
GNP sensor in the presence of unmodified HSA is ~520 nm, which is comparable to
absorption of dispersed gold nanoparticles in water. No significant change in the visible
absorption spectra was observed in response to increasing concentrations of unmodified
HSA over the concentration range investigated in this study. Conversely, the absorption
Langmuir. Author manuscript; available in PMC 2009 March 03.
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spectra of the sensor in the presence of an equivalent concentration range of HSA–
homocystamide have red-shifted extended plasmon bands (Figure 2b). A proportional
increase in UV absorption at the protein absorption bands ~220–280 nm was also observed
in response to increasing concentrations of both unmodified HSA and HSA–homocystamide
in the sensor solutions. A representative plot of the colorimetric response of the GNP sensor
detected at 620 nm in the presence of HSA–homocystamide is provided in the Supporting
Information (Figure S2). The colorimetric response was found to be linear (r2 = 0.9849) over
a range of HSA concentrations (2.8–28 mg/mL). The limit of detection (LOD) and
calibration sensitivity for the method were 2.3 mg/mL and 2.7 AU·(μg/mL)−1, respectively.
Collectively, these results suggest that the colorimetric signal produced by the GNP sensor
is due to HTL modification-directed nanoparticles assembly and not salt-induced
nanoparticle aggregation. Moreover, the stability of the GNP sensor in the HSA-phosphate
buffer solutions suggests that the GNP sensor will be stable in the presence of human sera
(vide infra).
Effect of Temperature on GNP Sensor-Protein Interactions
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Many GNP sensors reported in the literature are designed such that nanoparticle assembly is
achieved via reversible noncovalent interactions.51–53 Consequently, the mechanisms for
nanoparticle assembly are often loosely bound and environment dependent. For example,
Mirkin et al. demonstrated temperature-dependent reversible nanoparticle assembly over a
decade ago using DNA-functionalized GNPs.54 This system exploits noncovalent DNA
hybridization interactions to produce a colorimetric signal that could be effectively
“switched on and off” by cycling the solution temperature between 0 and 80 °C, the latter of
which is well above the dissociation temperature of the DNA–nanoparticle complex.
Additionally, a temperature- and pH-sensitive Hcy GNP sensor was recently developed by
Lim et al.33 This novel GNP sensor utilizes reversible zwitterionic-type interactions to
generate a colorimetric response.
A distinguishing characteristic of the proposed GNP sensor for protein homocystamide is
that it was designed to exhibit essentially irreversible binding behavior via thiol binding
interactions. In principle, a tightly bound nanoparticle–protein assembly would allow for
highly stable and long-lived colorimetric detection. Consequently, it was found that sensor
solutions containing HSA–homocystamide incubated in an 80 °C water bath for 20 min
exhibited remarkable stability as indicated by a persistent colorimetric signal. Only a very
slight increase in colorimetric signal was observed after exposing the sensor solutions to 80
°C for ~10 min (data not shown). This result is likely caused by additional GNP binding
sites being exposed due to thermal denaturation of the modified protein.
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Confirmation of Modification-Directed Nanoparticle Assembly
Transmission electron microscopy (TEM) was used to image the GNP sensor in the presence
of HSA and HSA homocystamide. As expected, the purple-colored GNP sensor–protein
homocystamide solutions contained oligomeric HSA, which appears as a dark sponge-like
film in the TEM image (33 000× magnification) shown in Figure 3a. The GNPs appear as
clearly defined black dots in the TEM images. Further examination of Figure 3a reveals an
assortment of nanoparticle clusters within the oligomeric protein network. The multiplicity
of shapes and sizes of the nanoparticle assemblies in the sensor specimen is consistent with
the broad extended plasmon bands observed at 620 nm (Figure 2b).55,56 The inset of Figure
3a (100 000× magnification) shows an example of modification-directed nanoparticle
assembly, a 4-nanoparticle cluster within the oligomeric protein network. Other regions
within the oligomeric protein network containing GNP clusters are highlighted in Figure S3
in the Supporting Information. These data suggest that both modification-induced protein
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oligomerization and modification-directed nanoparticle assembly occur concomitantly in the
GNP sensor solutions containing protein homocystamide.
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In contrast, neither nanoparticle assembly nor protein oligomerization is observed in a
specimen prepared from the red-colored GNP sensor solution containing unmodified HSA
(Figure 3b). The unmodified protein appears as dark semitransparent spots in the TEM
images. Closer examination of the sensor specimens containing unmodified HSA reveals
that the spherical GNPs are randomly dispersed throughout the specimen within individual
protein spots. The inset of Figure 3b shows GNPs in the presence of unmodified HSA at 100
000× magnification. Nanoparticle assembly is not induced by unmodified HSA, presumably
due to the lack of protein homocystamide binding sites. The absence of significant
nanoparticle assembly in the unmodified protein sample is consistent with the absorption
spectra shown in Figure 2a and consistent with the expected results for this detection
scheme.
Proposed Dectection Scheme for Protein Homocystamide in Human Serum
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Biochemical sensor design requires careful consideration of the intended sample matrix.
Blood and urine samples have been traditionally collected from patients for use in generic
clinical diagnostics. Urine analysis is a versatile medical screening procedure that has been
used historically for the in vitro detection of a number of physiologically relevant analytes
including illicit drugs, steroids, and numerous other analytes. The detection of HTL in
urinary excretions has been reported.57 However, the existence of substantial amounts of
protein homocystamide in urinary excretions is not expected because of the relatively low
protein content of urine. In contrast, human serum is a more ideal sample medium for the
protein sensor because it is relatively protein rich and thus more likely to contain detectable
levels of protein homocystamide. Another potential advantage of working with human
serum is that it is already routinely screened for other cardiovascular disease risk factors
such as cholesterol.
Unlike the purified HSA used in the previous studies, human serum is a complex medium
that consists of an assortment of proteins and small molecules, including carbohydrates,
drugs, hormones, etc., which may exist as free or protein-bound species. Human serum also
contains various thiol-containing species that could interfere with the GNP sensor. For
example, cysteine (Cys),56 glutathione,56 and Hcy33 are typically found at micromolar
concentrations in human sera. Fortunately, these low molecular weight species can be easily
removed from sera by use of a molecular cutoff filter device prior to treatment with the GNP
sensor.
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Frozen whole human sera collected and pooled from healthy adult donors were purchased
from Sigma-Aldrich (St. Louis, MO) for use in this component of our study. The sera
solutions were faintly yellow in color and slightly turbid due to sparingly soluble
components. The protein content of the sera was determined by a gravimetric assay of
lyophilized 1 mL aliquots after washing with deionized water. The average protein
concentration of the aliquots was 52.4 ± 6.7 mg/mL (n = 4). Sera were typically diluted with
phosphate buffer to obtain ~65% (v/v) serum solution in order to decrease the viscosity and
turbidity. The diluted serum was post-translationally modified with HTL in vitro as
previously described. Scheme 2 depicts the proposed scheme for detecting serum protein
homocystamide using the GNP sensor. First, the protein modification mixture is purified by
use of centrifugal 10 kDa molecular cutoff (MWCO) filters. Next, the modified protein
homocystamide retained by the MWCO filter is promptly reconstituted with phosphate
buffer in order to obtain a stock solution. The resultant protein homocystamide is then
immediately treated with the GNP sensor. Finally, the resultant GNP–protein
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homocystamide solution is diluted and transferred to a cuvette for monitoring of the
colorimetric response.

NIH-PA Author Manuscript

Representative absorption plots of the sensor under various experimental conditions are
shown in Figure 4. Similar to the HSA model studies, unmodified sera were found to be
reasonably stable and did not produce appreciable shifts in the plasmon resonance band over
the sera concentration range investigated in this study (Figures 4a). Consistent with the HSA
model studies, the sensor also produces extended plasmon resonance bands in the presence
of serum protein homocystamide (Figure 4b). Figure 4c is a comparison plot of sensor signal
versus serum protein concentration. It is apparent that the colorimetric signal detected at 620
nm increases in response to increasing concentrations of serum protein homocystamide but
remains relatively constant in the presence of equivalent concentrations of unmodified sera.
Notably, the sensor response deviates from linearity at modified serum concentrations lower
than ~5 mg/mL, giving a background signal of ~0.12 AU. This effect is partially attributed
to the GNPs being sparingly soluble in the phosphate buffer at low protein concentrations,
which produces increased sample turbidity and light scattering. The colorimetric response in
the range of 6.0–14 mg/mL modified serum protein provides excellent linearity (r2 =
0.9994) and a calibration sensitivity of 13.6 AU· (μg/mL)−1. The calculated LOD of the
serum method is 5.2 mg/mL.
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Human plasma can contain from 0.1 to 13 μM protein homocystamide, which is comparable
to the mg/mL protein concentration range.58 Accordingly, a solution containing 2.3 mg/mL
sera homocystamide and 0.7 mM GNP was allowed to react as previously described. The
resultant solution containing the HSA–homocystamide–GNP complex was serially diluted
with ultrapure water in order to evaluate the dilutional stability of the protein
homocystamide–GNP assembly at concentrations well below the physiologically relevant
range. The resultant curve exhibited excellent linearity (r2 = 0.9899), which is expected for a
tightly bound colorimetric complex (Figure S4, Supporting Information). The sensor also
provided an exceptional calibration sensitivity, 0.30 AU·(ng/mL)−1. These data further
support the hypothesis of modification-directed nanoparticle assembly via chemisorption
and intermolecular disulfide bonding interactions.
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Overall, the proposed GNP sensor exhibited exceptional performance for the detection of the
in vitro modified serum protein species used in these studies. This is largely because freshly
prepared protein homocystamide was promptly treated with the sensor, thereby minimizing
the effects of auto-oxidation in the protein reaction mixture. However, essentially all of the
protein homocystamide produced in vivo exists in an oxidized state and would thus be
unavailable for binding with the sensor. Therefore, the issue of reducing the oxidized protein
homocystamide species must be addressed prior to applying this method to screening
clinical samples containing in vivo synthesized serum protein homocystamide.

Conclusions
We demonstrated a straightforward colorimetric method for the detection of serum protein
homocystamide, an emergent cardiovascular disease biomarker. GNP assembly was
observed only in the presence of serum protein homocystamide. TEM images of the GNP
sensor in the presence of unmodified and HTL-modified serum protein are consistent with
the spectroscopy data. The TEM images are also indicative of modification-directed
nanoparticle assembly as well as modification-induced protein oligomerization. The
nanoparticle–protein homocystamide complex exhibited excellent stability and irreversible
binding behavior under the condition used in this study. Studies are underway to adapt this
model GNP biochemical sensor for use in clinical sera samples. On the basis of our studies
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to date, we believe that the approach reported here will lead to the development of a GNP
sensing scheme that could aid in the rapid detection and diagnosis of cardiovascular disease.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Photographs of the gold nanoparticle (GNP) sensor: (a) in the absence of protein, (b) in the
presence of unmodified HSA (9.2–85.2 mg/mL), and (c) in the presence of HSA–
homocystamide (9.2–85.2 mg/mL). All samples were prepared in 100 mM phosphate, 0.2
mM EDTA buffer. Each cuvette contains 0.3 mM GNP.
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Figure 2.
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UV–vis absorption spectra of GNP sensor solutions shown in Figure 1: (a) unmodified HSA
and (b) HSA protein homocystamide. Extended plasmon bands are only observed for sensor
solutions containing HSA–homocystamide. The arrows indicate the change in absorption
with increasing HSA or HSA–homocystamide.
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Figure 3.
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Representative transmission electron microscopy (TEM) images of the GNP sensor (a) in
the presence of HSA–homocystamide at 33 000× magnification (inset shows 100 000×
magnification of a 4-nanoparticle cluster assembly within the oligomeric protein network)
and (b) in the presence of unmodified HSA (inset shows 100 000× magnification of
unassembled GNPs surrounded by unmodified HSA). The arrows indicate the location of the
insets in lower magnification images.
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Figure 4.

Visible absorption spectra of the GNP sensor in response to human sera: (a) in the presence
of unmodified human sera and (b) in the presence of human serum homocystamide. (c)
Sensor response at 620 nm in the presence of modified (○) and unmodified (■) sera versus
human serum concentration (2–14 mg/mL). The arrow indicates the change in signal at 620
nm with increasing concentrations of human serum homocystamide.
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Scheme 1.

Proposed Colorimetric Gold Nanoparticle Sensor for Homocysteine Thiolactone-Induced
Protein Modification
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Scheme 2.

Proposed Scheme for Detection of Protein Homocystamide in Human Sera
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